Clinical trials
Breast Tumor clinical trials
Below are recruiting breast tumor clinical trials, each written for real people, not researchers. We’re tracking 340 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06629233Enrolling by invitation
New immunotherapy targets for estrogen-receptor positive breast cancer
This trial tests a new technique to find unique targets on breast cancer cells that could be used for future immunotherapies. It focuses on women with estrogen-receptor positive primary breast cancer.
Ghent, East-FlandersAges 18 years+ - NCT07101601RecruitingPhase 1
Testing DM5167 for advanced solid tumors with BRCA mutations
This trial is testing a new drug called DM5167 for people whose advanced solid tumors have a BRCA1 or BRCA2 gene mutation. The goal is to see if the drug can shrink tumors or slow their growth.
Gyeonggi-doAges 19 years+ - NCT05782686Recruiting
Shaving wound skin regularly after breast-conserving surgery
This study looks at whether regularly removing (shaving) small amounts of skin during recovery can improve surgical healing and outcomes. It focuses on people having breast-conserving surgery for certain early breast cancers.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT06103669Recruiting
Local treatment for limited cancer spread
This trial tests whether using local treatments (like targeted radiation or ablation) on a few new spots of cancer can help people whose cancer is otherwise stable on their current treatment. It enrolls people with various solid tumors, such as breast, gynecologic, head & neck, sarcoma, or other types.
Sacramento, CaliforniaAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT07211178Recruiting
Tracking cancer DNA in blood to detect early return of breast cancer
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
Birmingham, AlabamaAges 18–99 - NCT06666439Recruiting
Tracking lobular breast cancer with a blood test
This study is testing a new blood test that looks for cancer DNA to track how lobular breast cancer responds to treatment. It is for people whose cancer has spread and who have not yet started treatment for the spread.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07021846Recruiting
Higher-dose radiation for early breast cancer in young women
This study tests a higher-dose, faster radiation treatment for young women with early breast cancer who have certain risk factors. The goal is to reduce the chance of cancer coming back while keeping side effects low.
RomaAges 18–50 - NCT07574671Recruiting
Ketogenic Diet Study for Early-Stage Breast Cancer
This study tests whether a ketogenic diet (high fat, low carb) can help change the environment around breast cancer tumors in ways that might slow cancer growth. You'll follow the diet for several months while researchers monitor your health and take measurements.
San Antonio, TexasAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Goodyear, ArizonaAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05360290Recruiting
Study checks cancer cells in breast tissue after surgery
This trial looks for circulating tumor cells—cancer cells that may travel in the blood—after standard breast cancer treatment, including chemotherapy before surgery and surgery itself. It may help doctors understand who might be at higher risk and tailor follow-up care.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06307249RecruitingPhase 1
Precision therapy for solid tumors targeting CDK4/6 and VEGF
This trial tests a combination of two targeted drugs for advanced solid tumors like colorectal, lung, breast, and genitourinary cancers. The goal is to see if blocking certain proteins and a long RNA molecule can slow tumor growth.
Tripoli, North LebanonAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Newport Beach, CaliforniaAges 18 years+ - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
New Haven, ConnecticutAges 18 years+ - NCT05525767RecruitingPhase 4
Bevacizumab plus chemo before surgery for HER2-negative breast cancer
This trial studies whether adding bevacizumab (an anti-blood-vessel medicine) to chemotherapy before surgery improves treatment outcomes for people with HER2-negative breast cancer. It’s mainly for tumors that are stage II to IIIC and have not had prior cancer treatment.
Shijiazhuang, HebeiAges 18 years+ - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Chicago, IllinoisAges 18 years+ - NCT05381038RecruitingPhase 1/Phase 2
Personalized azacitidine combinations for breast or stomach cancer
This Phase 1/2 trial tests different combinations that include azacitidine, chosen based on your tumor’s lab “response markers” and past drug-sensitivity screening. It aims to find safer dosing and see whether these personalized combinations can shrink solid tumors such as breast or stomach cancer.
SingaporeAges 21–99 - NCT05740956RecruitingPhase 1
Drug study for cancers with HRR gene or HRD changes
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Beijing, Beijing MunicipalityAges 18–75 - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Newport Beach, CaliforniaAges 18 years+ - NCT01034033Recruiting
Blood and tumor genetic study for BRCA and related risks
This study collects blood (and possibly tumor tissue) to learn how certain inherited gene changes relate to breast and ovarian cancer risk. It may help researchers understand which people are most likely to develop these cancers and how tumors differ in high-risk patients.
Stanford, CaliforniaAges 18 years+ - NCT05160480Enrolling by invitation
Total-body PET scan using FDA-approved tracers for prostate or NET cancer
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Sacramento, CaliforniaAges 18 years+
Hear when a new Breast Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast tumor?
- Yes. Clin2 currently lists 340 recruiting breast tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.